FRE Share Price Performance
AU$0.078
0.03 (62.50%)
Price AU$0.078
Share PriceAU$0.078
FRE Community Narratives
There are no narratives available yet.
Recent FRE News & Updates
No updates
Firebrick Pharma Limited Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.0077
- Gross Margin
- 91.68%
- Net Profit Margin
- -152.38%
- Debt/Equity Ratio
- 0%
Firebrick Pharma Limited Competitors
About FRE
- Founded
- 2012
- Employees
- n/a
- CEO
- WebsiteView website
Firebrick Pharma Limited engages in the development and commercializing of novel formulations for the uses of povidone iodine in Australia. The company offers broad-spectrum antimicrobial nasal spray for the treatment of common cold under the Nasodine name. It also operates in the United states and Singapore. Firebrick Pharma Limited was incorporated in 2012 and is based in Melbourne, Australia.
Australian Market Performance
- 7 Days: 0.7%
- 3 Months: 7.6%
- 1 Year: 14.0%
- Year to Date: 6.4%
Over the last 7 days, the market has remained flat, with no particular sector making any big moves this week. More promisingly, the market is up 13% over the past year. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading